Raleigh-based Muses Labs, which is bringing to market a next-generation personalized combination therapy for Alzheimer’s disease, has raised nearly $800,000 of a $3 million equity offering, according to a regulatory filing.
The company’s recommended therapies are based on the “metabolic enhancement for neurodegeneration” (MEND) protocol, which precisely targets the dozens of underlying biological mechanisms that trigger Alzheimer’s disease. It’s web site says the company relies upon advanced software and big-data analytics, and incorporates decades of medical research.
The company raised $785,253 from 16 investors and says the money will be used for working capital, including compensation of its management team according to the filing with the U.S. Securities and Exchange Commission.
Vik Chandra is CEO of Muses Labs and John Q. Walker is chief technology officer.
Muses Labs: https://museslabs.com/about/
SEC filing: http://www.sec.gov/Archives/edgar/data/1612369/000161236915000001/xslFormDX01/primary_doc.xml